iCHIP study: Effect of Immune Checkpoint Inhibitors on HIV persistence: An observational study among HIV patients with cancer
| Study type |
Summary |
Inclusion Criteria |
Participation requirements | Status |
| Proof-of-concept study | The main reason why HIV cannot be cured at the moment is because HIV is able to hide in resting long-lived cells of the immune system. To achieve a cure for HIV, we need to develop therapies that are able to target and eliminate this pool of long-lived infected cells. One way to eliminate infected cells is through giving the immune system a boost using drugs called immune checkpoint blockers. These drugs were developed for different forms of cancer and have shown very good activity against some cancers. These drugs can block proteins called PD-1 and CTLA-4. Currently, only people with cancer are able to receive these medications. The aim of this study is to assess whether anti-PD1 or anti-CTLA4 can eliminate long lived forms of virus. |
|
Participation in this study only requires involvement for up to 4 immunotherapy treatments. You choose whether to give extra research blood samples during your 3rd and 4th immunotherapy infusions only, or during each of the four infusions. Before the start of your first infusion with an immunotherapy, and after enrolment into this study, 56 mL (nearly 3 tablespoons) of blood for research will be taken. Extra blood will then be collected for research-specific HIV assays at the following timepoints during treatment:
After 8 weeks post your fourth infusion, 56 mL (nearly 3 tablespoons) of blood for research will be taken. |
Currently recruiting |
Study contact
Alfred Clinical Research Unit on 03 9076 6908
.png)